Corcept Therapeutics (CORT) Stock Price, Quote & News

Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also develop...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 327 3270

Website: www.corcept.com

Address:

101 Redwood Shores Parkway, Redwood City, United States

RunnerSignals Aug. 4 at 8:41 PM

comeback vibes today $CORT $DPRO $AGIO $YMM $LC all dipped hard midday but bounced back stronger at the close

0 · Reply

RandyCarson859 Aug. 4 at 12:57 PM

$CORT From Startup ➝ Launch Phase Forget pre-revenue. WKSP is now: ✅ Products in production ✅ Dealer network built ✅ Patents filed & protected ✅ Govt contracts incoming It's go-to-market time - not a "maybe" anymore

0 · Reply

Daniech0514 Aug. 3 at 5:01 PM

$CORT I believe this will be in the 100s next year. With approval of Relicorilant for cushings and the expanded patient population. Plus new ovarian cancer drug pending approval in December for each. Not to mention upcoming trials in Mash, ALS and other cancer indications.

0 · Reply

ZacksResearch Aug. 1 at 4:58 PM

$CORT beats on EPS but cuts '25 revenue view — why shares are sliding 👀 Q2 earnings topped expectations, but revenue came in light — and the 2025 guidance just got trimmed. Full breakdown here 👉 https://www.zacks.com/stock/news/2649941/corts-q2-earnings-top-mark-revenues-lag-25-view-cut-stock-down?cid=sm-stocktwits-2-2649941-teaser-5514&ADID=SYND_STOCKTWITS_TWEET_2_2649941_TEASER_5514

0 · Reply

ZacksResearch Aug. 1 at 3:27 PM

$CORT beats EPS estimates, but why the pre-market dip? 🤔 Earnings came in at 29 cents, topping the Zacks Consensus Estimate of 23 cents. However, revenues missed expectations and the lowered 2025 guidance might have hurt investor sentiment, pushing shares down 4.7% in pre-market trading. 📉 Full breakdown here 👉 https://www.zacks.com/stock/news/2649941/corts-q2-earnings-top-mark-revenues-lag-25-view-cut-stock-down?cid=sm-stocktwits-2-2649941-body-5422&ADID=SYND_STOCKTWITS_TWEET_2_2649941_BODY_5422

1 · Reply

RodneyLeach917 Aug. 1 at 3:02 PM

$CORT Watch it or don’t. QNTM doesn’t care. But when it breaks, don’t say “no one told me.” You’ve been told 💬📢

0 · Reply

aristocks Aug. 1 at 1:56 PM

$CORT Looking OK in a sea of read.. Keep calm and do not take hasty decision.. Trying to recapture long term up trend!

0 · Reply

d_risk Aug. 1 at 1:45 PM

$CORT - Corcept Therapeutics Incorporated Common Stock - 10Q - Updated Risk Factors CORT’s 10-Q risk update highlights new R&D-related risks, detailed generic competition for Korlym, intensified U.S. federal regulatory and Medicaid pressures, expanded cybersecurity and data privacy concerns, stock volatility drivers including analyst coverage risks, and governance factors tied to concentrated insider ownership and charter provisions. #Pharmaceuticals #Cybersecurity #RegulatoryPressure #GenericCompetition #R&DRisks 🟢 Added 🟠 Removed https://d-risk.ai/CORT/10-Q/2025-07-31

0 · Reply

JarvisFlow Aug. 1 at 12:30 PM

Piper Sandler updates rating for Corcept Therapeutics ( $CORT ) to Overweight, target set at 131 → 121.

0 · Reply

EWindeed Jul. 31 at 9:14 PM

$CORT $54

3 · Reply

Corcept Therapeutics Incorporated (CORT) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:05 PM EDT - 4 days ago

Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update

Jul 24, 2025, 4:05 PM EDT - 11 days ago

Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call

Jul 14, 2025, 8:00 AM EDT - 21 days ago

Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer

Jun 30, 2025, 1:45 AM EDT - 5 weeks ago

Beyond Cushing's: The Undervalued Potential Of Corcept's Cortisol Modulators

Jun 23, 2025, 4:30 PM EDT - 6 weeks ago

Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care

Jun 13, 2025, 5:37 PM EDT - 7 weeks ago

Corcept: Remains A Strong Buy On Recent Weakness And Aggressive Sales Force Hiring

Jun 11, 2025, 7:00 AM EDT - 7 weeks ago

20 stocks you should avoid — no matter how well the market does

CPRX CRK CRNC DDD LUMN LYV MGPI

Jun 5, 2025, 6:00 AM EDT - 2 months ago

Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting

Jun 2, 2025, 11:15 AM EDT - 2 months ago

Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer

May 5, 2025, 8:34 PM EDT - 3 months ago

Corcept Therapeutics Incorporated (CORT) Q1 2025 Earnings Call Transcript

May 5, 2025, 4:05 PM EDT - 3 months ago

CORCEPT THERAPEUTICS ANNOUNCES FIRST QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Apr 28, 2025, 4:05 PM EDT - 3 months ago

CORCEPT THERAPEUTICS TO ANNOUNCE FIRST QUARTER FINANCIAL RESULTS, PROVIDE CORPORATE UPDATE AND HOST CONFERENCE CALL

Apr 23, 2025, 11:30 AM EDT - 3 months ago

CORCEPT TO PRESENT LATE-BREAKING DATA FROM PIVOTAL PHASE 3 ROSELLA TRIAL OF RELACORILANT IN PLATINUM-RESISTANT OVARIAN CANCER AT ASCO 2025

Apr 22, 2025, 5:23 PM EDT - 3 months ago

Corcept: Maintaining Strong Buy Even After 4Q Revenue And Earnings Miss

Apr 21, 2025, 8:00 AM EDT - 3 months ago

Diabetes Care Publishes Results From Prevalence Phase Of Corcept's CATALYST Trial In People With Difficult-To-Control Type 2 Diabetes

Apr 15, 2025, 4:00 PM EDT - 3 months ago

It's Still Early For Corcept: With Multiple Growth Opportunities Ahead, It's No Longer Just A One Drug Wonder

Apr 7, 2025, 8:00 AM EDT - 4 months ago

Corcept Initiates Trial of Relacorilant Plus Nab-Paclitaxel and Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer

Apr 1, 2025, 1:43 PM EDT - 4 months ago

Corcept Therapeutics: New PROC SOC Treatment Option With Relacorilant Data Release

Apr 1, 2025, 7:15 AM EDT - 4 months ago

Corcept Therapeutics: The ROSELLA Trial Presents A Major Win For The Company

Mar 31, 2025, 3:01 PM EDT - 4 months ago

Corcept Therapeutics Stock Jumps On Upbeat Ovarian Cancer Trial Data, Analysts Boost Price Forecast

Mar 31, 2025, 8:18 AM EDT - 4 months ago

Corcept's ovarian cancer combination drug meets main goal in late-stage study

Mar 31, 2025, 8:00 AM EDT - 4 months ago

Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer

Mar 12, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Bronstein, Gewirtz & Grossman, LLC (CORT) Investors to Inquire about Securities Investigation

Mar 11, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Shareholders to Inquire about Securities Investigation

Mar 10, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Connect

Mar 10, 2025, 8:00 AM EDT - 5 months ago

Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Mar 9, 2025, 10:00 AM EDT - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Corcept Therapeutics Incorporated (CORT) And Encourages Shareholders to Reach Out

Mar 7, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Shareholders to Learn More About the Investigation

Mar 6, 2025, 10:00 AM EST - 5 months ago

Corcept Therapeutics Incorporated (CORT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Mar 5, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Corcept Therapeutics Incorporated (CORT) And Encourages Investors to Connect

Mar 4, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Stockholders to Inquire about Securities Investigation

Mar 4, 2025, 7:03 AM EST - 5 months ago

Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025

GILD PRVA TGTX TKO

Mar 3, 2025, 4:05 PM EST - 5 months ago

FDA Files Corcept's New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism

Mar 3, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Investors to Learn More About the Investigation

Mar 2, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Corcept Therapeutics Incorporated (CORT) and Encourages Stockholders to Learn More About the Investigation

Feb 28, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Corcept Therapeutics Incorporated (CORT) Investors to Inquire about Securities Investigation

Feb 27, 2025, 10:00 AM EST - 5 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Corcept Therapeutics Incorporated (CORT) And Encourages Investors to Reach Out

Feb 26, 2025, 9:53 PM EST - 5 months ago

Corcept Therapeutics, Inc. (CORT) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 4:05 PM EST - 5 months ago

Corcept Therapeutics Announces Fourth Quarter and Full-Year 2024 Audited Financial Results and Provides Corporate Update

RunnerSignals Aug. 4 at 8:41 PM

comeback vibes today $CORT $DPRO $AGIO $YMM $LC all dipped hard midday but bounced back stronger at the close

0 · Reply

RandyCarson859 Aug. 4 at 12:57 PM

0 · Reply

Daniech0514 Aug. 3 at 5:01 PM

0 · Reply

ZacksResearch Aug. 1 at 4:58 PM

0 · Reply

ZacksResearch Aug. 1 at 3:27 PM

1 · Reply

RodneyLeach917 Aug. 1 at 3:02 PM

$CORT Watch it or don’t. QNTM doesn’t care. But when it breaks, don’t say “no one told me.” You’ve been told 💬📢

0 · Reply

aristocks Aug. 1 at 1:56 PM

$CORT Looking OK in a sea of read.. Keep calm and do not take hasty decision.. Trying to recapture long term up trend!

0 · Reply

d_risk Aug. 1 at 1:45 PM

0 · Reply

JarvisFlow Aug. 1 at 12:30 PM

Piper Sandler updates rating for Corcept Therapeutics ( $CORT ) to Overweight, target set at 131 → 121.

0 · Reply

EWindeed Jul. 31 at 9:14 PM

$CORT $54

3 · Reply

moorenard1 Jul. 31 at 8:47 PM

$CORT Record Revenue + Company bought back $115MM in stock! Shorts are in a death spiral!

1 · Reply

stewpackard Jul. 31 at 8:28 PM

$CORT here come the 50s again bummer

3 · Reply

druvaciam Jul. 31 at 8:24 PM

$CORT Lowered 2025 revenue guidance of $850 – $900 million, not good

2 · Reply

stewpackard Jul. 31 at 8:07 PM

$CORT crashing

2 · Reply

HotStockScreener Jul. 31 at 4:34 PM

$CORT Earnings after close. Great risk/reward at this point

1 · Reply

Daniech0514 Jul. 31 at 10:11 AM

$CORT earnings call after the bell. I will be listening to see if any updates on patent infringement case. Hopefully we will see some revenue growth starting from their publication of Catalyst research in type2 diabetes. And I hope someone ask about next steps with ALS drug.

0 · Reply

NVDAMillionaire Jul. 30 at 6:28 PM

$CORT Really good write-up that perfectly summarizes CORT's present situation. So if you want to bring your CORT knowledge up to date or just discover CORT, this is required reading. https://beyondspx.com/article/corcept-therapeutics-unlocking-cortisol-s-potential-across-endocrinology-and-oncology-nasdaq-cort

0 · Reply

gucag006 Jul. 29 at 12:05 AM

$CORT Any investor, skilled or amateur, knows that there is absolutely no chance for the following issues to double from here: GLD, SLV, NVDA or cryptos. You know, the consensus is that CORT will more than double a year from now - 3rd in line after death and taxes in life. https://finance.yahoo.com/news/h-c-wainwright-remains-bullish-060748515.html

1 · Reply

OX50 Jul. 25 at 8:04 PM

$CORT Ovarian cancer has killed millions of women in this country and it is a real thing that we are in dire need to have a drug that can save women whoever are diagnosed with the cancer. It is so deadly that when it's found too late, patients die within 6 months of time frame. I pray Corcept's cancer drug will get approved and start saving lives.

0 · Reply

OX50 Jul. 25 at 7:56 PM

$CORT My mother in law and my step mother in law both died by Ovarian cancer around 65 of age. The cancer took both of them so fast in less than 9 months. Corcept is an easy triple when their Ovarian cancer drug gets approved by FDA. Corcept has reached the stage 3 approval by FDA. No pain, no gain. I am in for a long term.

0 · Reply

OX50 Jul. 25 at 7:49 PM

$CORT Charles Schwab has a target price of $138 for Corcept. The company is seeking approval for relacorilant in combination with nab-paclitaxel for treating patients with platinum-resistant ovarian cancer. This marks a new NDA for relacorilant. Last December, the company submitted an NDA for relacorilant to the FDA for treating patients with hypercortisolism (Cushing's syndrome). The NDA for relacorilant in platinum-resistant ovarian cancer was based on data from the pivotal phase III ROSELLA study and phase II studies. Recently, the company announced that the ROSELLA study met its primary endpoint of improved progression-free survival, as assessed by blinded independent central review (PFS-BICR). Per management, data from the ROSELLA study suggested that the combo of relacorilant plus nab-paclitaxel has the potential to become a new standard of care for patients with platinum-resistant ovarian cancer.

0 · Reply

aristocks Jul. 23 at 3:48 PM

$CORT cannot stay above 70$ 🤷🏾

0 · Reply

Market Cap	7.32B
Revenue (ttm)	675.04M
Net Income (ttm)	141.21M
EPS (ttm)	N/A
PE Ratio	59.44
Forward PE	48.24
Profit Margin	20.92%
Debt to Equity Ratio	0.00

Volume	1,779,748
Avg Vol	1,359,878
Day's Range	N/A - N/A
Shares Out	106.05M
Stochastic %K	75%
Beta	0.20
Analysts	Strong Sell
Price Target	$138.25